Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 6,194 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Parkinson Disease
Interventions: Stanford Glove; Device
Lead sponsor: Stanford University; Other
Eligibility: 35 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
Interventions: Hematopoietic Cell Transplant, Letermovir; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Health Coaching; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 95 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rett Syndrome
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas

Conditions: Substance Use Disorder (SUD)
Interventions: Regional Anesthesia, Hydromorphone Patient Controlled Analgelsic, Epidural local anesthetic infusion; Drug · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Metastatic Breast Cancer
Interventions: Treatment recommendation; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Heart Failure
Interventions: EHR-based GDMT Optimization; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Gallup, New Mexico • Tohatchi, New Mexico

Conditions: Acute Pain, Surgery
Interventions: NeuroIDgenetix Test Panel; Other
Lead sponsor: AltheaDx; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Seizures, Encephalopathy
Interventions: EEG monitoring and treatment of EEG seizures; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Hour to 72 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Substance Use Disorders, Overdose, Opioid Use Disorder, Alcohol Use Disorder
Interventions: Substance Misuse Assistance Response Team (SMART), Usual Care Group; Behavioral · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Sanfilippo Syndrome
Interventions: Recombinant human heparan N-sulfatase [rhHNS]; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Months to 48 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina

Conditions: Pain
Interventions: aspirin and ketamine, Nurtec (Rimegepant); Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Medication Errors and Other Product Use Errors and Issues
Interventions: Med@HOME Mobile App; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions: Dronabinol Capsules, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hosuton, Texas • Houston, Texas

Conditions: Hepatitis C
Interventions: BMS-650032, BMS-790052; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus Type 2 - Insulin-Treated
Interventions: Smartphone application and web portal, Standard Insulin Therapy Education; Device · Behavioral
Lead sponsor: Linda Siminerio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX); Biological · Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more

Conditions: Myelodysplastic Syndromes
Interventions: cenersen, Dexamethasone; Drug
Lead sponsor: Eleos, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Autism, Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate-extended release, Methylphenidate-immediate release, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 7 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Stroke
Interventions: SCM, SCM and VSSP; Other
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Lansing, Michigan • Ypsilanti, Michigan

Conditions: Chronic Lymphocytic Leukemia, Richter's Transformation
Interventions: Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib; Drug
Lead sponsor: Christine Ryan; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more

Conditions: Persistent Depressive Disorder
Interventions: Behavioral Activation for return to work; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: High Grade Glioma, Anaplastic Astrocytoma
Interventions: DB107-RRV, DB107-FC; Drug
Lead sponsor: Ashish Shah; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: UX007, Placebo; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year to 100 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more

Search by objective public record fields.

Vibrotactile Coordinated Reset for Parkinson's Patients of a More Variable Population

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Aides in Respiration Health Coaching for COPD

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.

Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

Heart Failure Optimization at Home to Improve Outcomes (Hozho): A Pragmatic Clinical Trial in Navajo Nation

Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures

The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy

Emergency Medicine Peer Outreach Worker Engagement for Recovery

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache

Meds@HOME App to Support Medication Safety

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

Drug-Drug Interaction Study in Healthy Subjects

My Dose Coach Mobile App to Support Insulin Titration and Maintenance

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Michigan Stroke Transitions Trial

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)